Literature DB >> 6520748

Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.

C C Peck, S L Beal, L B Sheiner, A I Nichols.   

Abstract

It is often difficult to specify weights for weighted least squares nonlinear regression analysis of pharmacokinetic data. Improper choice of weights may lead to inaccurate and/or imprecise estimates of pharmacokinetic parameters. Extended least squares nonlinear regression provides a possible solution to this problem by allowing the incorporation of a general parametric variance model. Weighted least squares and extended least squares analyses of data from a simulated pharmacokinetic experiment were compared. Weighted least squares analysis of the simulated data, using commonly used weighting schemes, yielded estimates of pharmacokinetic parameters that were significantly biased, whereas extended least squares estimates were unbiased. Extended least squares estimates were often significantly more precise than were weighted least squares estimates. It is suggested that extended least squares regression should be further investigated for individual pharmacokinetic data analysis.

Mesh:

Substances:

Year:  1984        PMID: 6520748     DOI: 10.1007/bf01060132

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  8 in total

1.  Radioligand Assay.

Authors:  D J Finney
Journal:  Biometrics       Date:  1976-12       Impact factor: 2.571

2.  Investigation of the effect of data error in the analysis of biological tracer data.

Authors:  J Myhill
Journal:  Biophys J       Date:  2008-12-31       Impact factor: 4.033

Review 3.  Fitting nonlinear models to data.

Authors:  R I Jennrich; M L Ralston
Journal:  Annu Rev Biophys Bioeng       Date:  1979

4.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

5.  Pharmacokinetics of digoxin: comparison of a two- and a three-compartment model in man.

Authors:  W G Kramer; R P Lewis; T C Cobb; W F Forester; J A Visconti; L A Wanke; H G Boxenbaum; R H Reuning
Journal:  J Pharmacokinet Biopharm       Date:  1974-08

6.  Weighting functions and data truncation in the fitting of multi-exponential functions.

Authors:  G L Atkins
Journal:  Biochem J       Date:  1974-01       Impact factor: 3.857

7.  Nonlinear least-squares regression programs for microcomputers.

Authors:  C C Peck; B B Barrett
Journal:  J Pharmacokinet Biopharm       Date:  1979-10

8.  Variability in derived parameters of furosemide pharmacokinetics.

Authors:  P Chennavasin; R A Johnson; D C Brater
Journal:  J Pharmacokinet Biopharm       Date:  1981-10
  8 in total
  42 in total

1.  A comparison of methods for estimating individual pharmacokinetic parameters.

Authors:  T Amisaki; S Eguchi
Journal:  J Pharmacokinet Biopharm       Date:  1999-02

2.  Robust population pharmacokinetic experiment design.

Authors:  Michael G Dodds; Andrew C Hooker; Paolo Vicini
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

Review 3.  Recommended reading in population pharmacokinetic pharmacodynamics.

Authors:  Peter L Bonate
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

4.  Pharmacokinetic parameter estimations by minimum relative entropy method.

Authors:  T Amisaki; S Eguchi
Journal:  J Pharmacokinet Biopharm       Date:  1995-10

5.  The effects of urine pH modification on the pharmacokinetics and pharmacodynamics of phenylpropanolamine.

Authors:  C L Zimmerman; M B O'Connell; I Soria
Journal:  Pharm Res       Date:  1990-01       Impact factor: 4.200

6.  D-optimal designs for parameter estimation for indirect pharmacodynamic response models.

Authors:  Leonid A Khinkis; Wojciech Krzyzanski; William J Jusko; William R Greco
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-11       Impact factor: 2.745

Review 7.  Methodological issues in pharmacokinetic-pharmacodynamic modelling.

Authors:  E Bellissant; V Sébille; G Paintaud
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

Review 8.  Expanding clinical applications of population pharmacodynamic modelling.

Authors:  C Minto; T Schnider
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

9.  Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana.

Authors:  E Johansson; M M Halldin; S Agurell; L E Hollister; H K Gillespie
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

10.  Pharmacokinetics of felodipine in patients with impaired renal function.

Authors:  B Edgar; C G Regårdh; P O Attman; M Aurell; H Herlitz; G Johnsson
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.